Thymopoiesis following HSCT; a retrospective review comparing interventions for aGVHD in a pediatric cohort

Copyright © 2018 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 193(2018) vom: 30. Aug., Seite 33-37
1. Verfasser: Flinn, A M (VerfasserIn)
Weitere Verfasser: Roberts, C F, Slatter, M A, Skinner, R, Robson, H, Lawrence, J, Guest, J, Gennery, A R
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2018
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Acute graft-versus-host-disease Corticosteroids Extracorporeal photopheresis Hematopoietic stem cell transplant Immunoreconstitution Thymopoiesis Adrenal Cortex Hormones Immunosuppressive Agents mehr... Tumor Necrosis Factor Receptor Superfamily, Member 7 Leukocyte Common Antigens EC 3.1.3.48
LEADER 01000naa a22002652 4500
001 NLM28055754X
003 DE-627
005 20231225025608.0
007 cr uuu---uuuuu
008 231225s2018 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2018.01.006  |2 doi 
028 5 2 |a pubmed24n0935.xml 
035 |a (DE-627)NLM28055754X 
035 |a (NLM)29395846 
035 |a (PII)S1521-6616(17)30780-5 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Flinn, A M  |e verfasserin  |4 aut 
245 1 0 |a Thymopoiesis following HSCT; a retrospective review comparing interventions for aGVHD in a pediatric cohort 
264 1 |c 2018 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 27.08.2019 
500 |a Date Revised 27.08.2019 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2018 Elsevier Inc. All rights reserved. 
520 |a Acute graft-versus-host disease (aGVHD) complicates allogeneic hematopoietic stem cell transplantation (HSCT), and is treated with topical and/or systemic corticosteroids. Systemic corticosteroids and aGVHD damage thymic tissue. We compared thymopoietic effect of topical steroid therapy, corticosteroids and extracorporeal photopheresis (ECP) in 102 pediatric allogeneic HSCT patients. We categorized patients into 4 groups: - no aGVHD, aGVHD treated with topical or systemic steroid, or ECP. Naïve CD4+CD45RA+CD27+ T-lymphocyte values at 3, 6, 9, 12months post-HSCT were recorded: for ECP patients, values were recorded at 3, 6, 9, 12months during ECP. Differences were compared using the Kruskal-Wallis test. 41 patients had no aGVHD, 23 had aGVHD treated topically or systemically (25), 13 received ECP. Rate of thymopoiesis was significantly different between all groups at all time-points post-transplant (p=0.002, p<0.001, p<0.001, p=0.001 respectively). Even mild aGVHD impairs thymopoiesis. Worst recovery was in ECP patients. Earlier institution of ECP may speed thymic recovery 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Acute graft-versus-host-disease 
650 4 |a Corticosteroids 
650 4 |a Extracorporeal photopheresis 
650 4 |a Hematopoietic stem cell transplant 
650 4 |a Immunoreconstitution 
650 4 |a Thymopoiesis 
650 7 |a Adrenal Cortex Hormones  |2 NLM 
650 7 |a Immunosuppressive Agents  |2 NLM 
650 7 |a Tumor Necrosis Factor Receptor Superfamily, Member 7  |2 NLM 
650 7 |a Leukocyte Common Antigens  |2 NLM 
650 7 |a EC 3.1.3.48  |2 NLM 
700 1 |a Roberts, C F  |e verfasserin  |4 aut 
700 1 |a Slatter, M A  |e verfasserin  |4 aut 
700 1 |a Skinner, R  |e verfasserin  |4 aut 
700 1 |a Robson, H  |e verfasserin  |4 aut 
700 1 |a Lawrence, J  |e verfasserin  |4 aut 
700 1 |a Guest, J  |e verfasserin  |4 aut 
700 1 |a Gennery, A R  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 193(2018) vom: 30. Aug., Seite 33-37  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:193  |g year:2018  |g day:30  |g month:08  |g pages:33-37 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2018.01.006  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 193  |j 2018  |b 30  |c 08  |h 33-37